Amgen (NASDAQ:AMGN) Shares Unloaded Rep. Maria Elvira Salazar

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Amgen stock on April 17th. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Carrier Global (NYSE:CARR) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Carrier Global (NYSE:CARR) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 4/24/2026.
• Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 4/22/2026.
• Purchased $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 4/20/2026.
• Purchased $15,001 – $50,000 in shares of Sherwin-Williams (NYSE:SHW) on 4/20/2026.
• Purchased $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 4/17/2026.
• Purchased $1,001 – $15,000 in shares of Voyager Technologies (NYSE:VOYG) on 4/14/2026.
• Purchased $15,001 – $50,000 in shares of Marvell Technology (NASDAQ:MRVL) on 4/6/2026.
• Purchased $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 4/6/2026.

Amgen Price Performance

Amgen stock traded up $6.70 during mid-day trading on Tuesday, hitting $336.29. 3,079,274 shares of the company were exchanged, compared to its average volume of 2,758,866. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The company has a market capitalization of $181.49 billion, a P/E ratio of 23.40, a PEG ratio of 3.33 and a beta of 0.44. The business’s 50 day simple moving average is $353.07 and its two-hundred day simple moving average is $342.21. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter last year, the business posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts forecast that Amgen Inc. will post 22.36 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.15%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Amgen

Large investors have recently modified their holdings of the stock. Anfield Capital Management LLC raised its position in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC increased its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Amgen in the fourth quarter worth about $26,000. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares in the last quarter. Finally, Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AMGN shares. Jefferies Financial Group started coverage on Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. TD Cowen reissued a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. The Goldman Sachs Group boosted their price objective on Amgen from $415.00 to $425.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Finally, Sanford C. Bernstein cut Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $357.12.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.